The developers described the panel in a scientific poster session on Tuesday at AACC 2022.

Spinal muscular atrophy is the leading inherited cause of infant death after cystic fibrosis; early diagnosis and treatment are crucial to giving affected newborns the best chances at healthy lives.

However, most newborn screening panels that use NGS do not detect this condition.

The most common form of spinal muscular atrophy is caused by an abnormal version of the gene SMN1, which produces a protein essential to nerve cells involved in muscle movement.

NGS panels -- which analyze hundreds of genes for disease-causing changes -- typically exclude SMN1 because of difficulty distinguishing it from another gene known as SMN2. The two differ only in the small spot on the SMN1 gene.

Using their NGS panel, Barra and his colleagues tested 52 DNA samples from spinal muscular atrophy patients and then compared the results to those from a single-gene polymerase chain reaction (PCR) test, a widely used method for diagnosing this condition.

After eliminating four samples for technical reasons, the researchers found that panel results for SMN1 and the single-gene test agreed in all cases.

Including spinal muscular atrophy on NGS panels means that "parents do not have to look for an additional test for [this condition]," Barra said in a statement, adding that it would save laboratories from performing an extra test for spinal muscular atrophy along with NGS newborn screening.

Smartphone app, blood test may predict clotting risk
A team of researchers led by Dr. Kelly Michaelsen of the University of Washington is developing a test that could quickly and inexpensively determine...

Improving kidney stone analysis, treatment with AI
To improve diagnosis and better guide treatment, researchers led by Patrick Day of the Mayo Clinic have developed artificial intelligence (AI)-trained...

Studies uncover findings on antibody responses, immunity
Findings from two studies add to a growing body of knowledge that is essential for guiding public health initiatives and might one day enable clinicians...

LumiraDx to discuss microfluidic technology at AACC
LumiraDx announced that it will host an industry workshop at AACC 2022 on Wednesday, describing the impact of its microfluidic technology on lateral-flow...

Cytovale to present new data on rapid sepsis test at AACC
Cytovale said Monday that it will present new data at AACC 2022 about its 10-minute IntelliSep test for sepsis and its associated system.